Connect with us

Politics

Psychedelics Decrim Activists Mark First Anniversary Of Denver’s Historic Psilocybin Mushroom Vote

Published

on

One year ago on Thursday, activists behind a first-of-its-kind drug policy reform ballot initiative in Denver were anxiously awaiting the results of a local vote that stood to set the city apart from any other in the country. Things didn’t look promising near the end of the night when they were behind—but as the votes continued to trickle in through the next day, it became official: The city had become the first place in the U.S. to decriminalize so-called magic mushrooms.

The Decriminalize Denver campaign defied odds and expectations. Psilocybin was just entering into the mainstream lexicon, there weren’t any large and monied psychedelics advocacy groups chipping in and voter confusion about what it meant to decriminalize—rather than allow retail sales like is the case for marijuana—threatened to derail the bold initiative.

But through a combination of education, outreach and innovation—as well as the open-mindedness of the local electorate—the campaign prevailed. More remarkable than the policy change in Denver, however, is the national grassroots movement it has inspired in the year since the historic vote.

Activists in more than 100 cities across the U.S. have now expressed interest in reforming their own psychedelics policies. Two more cities—Oakland and Santa Cruz—went a step further than Denver and decriminalized a wide range of entheogenic substances such as ayahuasca and ibogaine.

Oregon advocates are close to qualifying a statewide ballot initiative to legalize psilocybin for therapeutic use for this November. Washington D.C. activists were approved to circulate a petition to decriminalize various psychedelics in the nation’s capital on Wednesday. A California campaign had hopes of putting psilocybin legalization on the ballot before the coronavirus pandemic. And psychedelics reform bills have been introduced in three state legislatures.

On the congressional level, Rep. Earl Blumenauer (D-OR) has endorsed the Oregon psilocybin initiative and Rep. Alexandria Ocasio-Cortez (D-NY) introduced an amendment to encourage research into the medical potential of psychedelics. That was defeated on the House floor, but she plans to file more legislation on the issue.

In other words, a lot has happened in a year. And it is difficult to believe that the movement for drug policy reform beyond cannabis would have organized and spread this quickly were it not for what happened in Denver. Kevin Matthews, who led that campaign and has since launched a national advocacy group called SPORE, told Marijuana Moment that he “always looked at Decriminalize Denver and the Denver Psilocybin Initiative as an experiment for how to change laws around psychedelics.”

“Denver was the first step and we still have a lot of work to do,” he said. “What I didn’t necessarily expect was how quickly the landscape would evolve and how it would be this massive, national—perhaps even global—conversation now.”

The success of the campaign “just shocked people,” he said. “I think it really showed that you have a committed, passionate group of people who are brave enough to step into this space and really put their blood, sweat and tears, energy and, in some ways, livelihoods on the line to progress something. We were another example of that, right?”

More and more examples have formed in the past year, with activists working overtime to convince local legislators and residents that criminalizing people for using entheogenic substances is the wrong path. Instead, the plants and fungi should be viewed through the lens of civil liberties and public health, they say, citing research indicating that these currently illicit drugs hold significant therapeutic potential for the treatment of conditions such as severe depression and post-traumatic stress disorder.

One of the main reform groups that has emerged in the space since Denver is called Decriminalize Nature (DN)—a national hub for campaigns to lean on as they pursue local and state policy changes. Chapters across the country are raising awareness, exploring the ballot process for reform and communicating with lawmakers about the need to take a new approach to psychedelics.

Larry Norris, who cofounded Decriminalize Nature, told Marijuana Moment that “Denver’s success cast light on a space beyond the veil of possibilities.”

“They were the first to bring the important conversation about decriminalization to the table, and in the end, the power of the people prevailed. Even the victory was a great underdog story,” he said. “To come back from behind, after almost every news organization reported the initiative had failed the previous evening, provided great media attention for the larger policy conversation. Their success also gave a boost of confidence to Decriminalize Nature, who was able to share Denver’s victory with the Oakland City Council-Members shortly before the public hearings began in Oakland.”

Oakland activists aren’t stopping at decriminalization, either, with plans now in the works to propose a local regulatory model for a limited retail system for entheogenic substances.

David Bronner, CEO of the activist soap company Dr. Bronner’s, which is funding several psychedelics reform campaigns across the country, told Marijuana Moment that the vote in Denver last year “showed that it’s now politically possible to win our right to life-saving psychedelic medicine at this moment of the cultural psychedelic renaissance, and directly paved the way for Decrim Oakland to make magic happen there, and the birth of now national and international Decrim Nature movement.”

“It set a good precedent of talking about psychedelic medicine in the healing therapeutic frame, with a strong educational component about proper preparation, set and setting, and integration after,” he said.

There have been some reform supporters who have questioned whether decriminalization campaigns could detract from the rigorous, federally authorized studies into the therapeutic benefits of psychedelics that are in the works. Author Michael Pollan, for example argued in a New York Times op-ed shortly after the Denver vote that “ballot initiatives may not be the smartest way” to change laws around the substances. He later seemed to walk back that stance somewhat after pushback from advocates, however.

Natalie Ginsberg, director of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), which is funding and gaining approval for clinical trials into several substances, told Marijuana Moment that for decades, “psychedelic research has been paving the way for psychedelic medicine, but medical access is not enough—decriminalization must go hand-in-hand with medicalization for a healthful society.”

Bronner also contended in a blog post last year that bringing the underground psychedelics world aboveground through a state-licensed treatment model in advance of federal approval “provides an example outside of the traditional pharma model for responsible regulated adult access to psilocybin therapy.”

“It’s also important to understand that the state ballot measure process is the only political mechanism that exists for providing this kind of broad responsible adult access,” whereas psychedelic-based pharmaceuticals could be less accessible, he said.

Advancements are being made in the traditional research realm as well, with Johns Hopkins University announcing last year that it is launching the nation’s first center devoted exclusively to studying psychedelic drugs.

What’s to come in the year ahead? The current pandemic might have created challenges for political campaigns of late, but assuming society returns to some level of normalcy, advocates anticipate an even bigger wave of reform—another year of progress that challenges the status quo of prohibition and demonstrates the need for a psychedelics renaissance.

Bronner predicted that “we’re going to see most large urban cities in America decriminalize mushrooms and plant medicines in the next few years,” adding that he believes Food and Drug Administration approval of psychedelic therapies will happen and Oregon will legalize psilocybin for therapeutic use. That will “pave the way to mainstream acceptance and widespread psychedelic healing of the people of the world by the end of the decade,” he said.

Norris conceded that it’s “uncertain how quickly things will reopen post COVID-19 shutdown and when city councils will be able to address these policies again” and the pandemic “obviously had a great impact on those with ballot initiatives who need to gather signatures.”

“However, many DN teams are working hard behind the scenes to prepare for the eventual reopening. Taking our cue from nature, DN is currently in a phase of nourishing our roots, rather than fruiting and blossoming,” he said, adding that the organization has been holding virtual meetings with activists across the country and globe. “Assuming things resume in a timely manner, we project at least five to seven more cities will Decriminalize Nature by the end of 2020.”

Among some drug policy reform advocates, there’s a lingering question about focusing decriminalization efforts on a singular class of substances, rather than ending the drug war altogether by removing criminal penalties for all currently illicit drugs.

Matthews said he agrees that reform shouldn’t end with psychedelics. “I absolutely support the broader decriminalization of all drugs,” he said. “Our campaign in many ways opened the door for us to have a direct conversation with the city—a very direct conversation with the city—about how it enforces their drug policy. We need alternatives to the current drug policy paradigm.”

“All substances absolutely need to be decriminalized because they’re mostly non-violent and victimless crimes, and we need to focus more on treatment where it’s necessary,” he said. “The psychedelics drug policy movement can very much inform and help galvanize the broader drug policy decriminalization movement. Denver is a good example of that based on the messaging we’ve got from the city.”

Ginsberg at MAPS said that “Denver’s move to deprioritize psilocybin arrests ignited communities across the country to mobilize to deprioritize all entheogenic plants, cacti and fungi, or ‘decriminalize nature’,” adding that she’s “hopeful that these psychedelic movements will join forces with broader coalitions to end the war on drugs and fully decriminalize all drugs.”

“In times of pandemic it’s clearer than ever that mass incarceration, and mass criminalization, are fundamentally incompatible with public health,” she said.

Broader decriminalization campaigns might not yet be taking off at the speed of the psychedelics reform movement, but there are proposed statewide initiatives in Oregon and Washington state to fully end the criminalization of drug possession while expanding treatment services.

In the meantime, Matthews had this to say to activists in the early stages of exploring psychedelics reform:

“Be committed, and that takes discipline. Folks definitely need to explore—both internally, to have experience with these substances to really understand it, and then find the others. That takes bravery because you’re stepping out as a psychedelics user in a sense. Then start broadcasting. Start sharing information. Social media, email your network—broadcast, broadcast, broadcast, and do it with integrity. Be very open about both the therapeutic and medical potential and the risks. That’s very important.”

“If you’re committed, a part of that involves faith and trust in the process,” he said. “This movement certainly has a mind of its own. If anyone out there wants to dedicate their livelihood to this, then they will be supported by the microverse.”

Decriminalization might be on the books now as Denver’s official policy thanks to the vote one year ago, but Matthews and other advocates are still at work educating city officials and ensuring that the change is implemented effectively, with an eye toward justice. A panel comprised of city officials, law enforcement and advocates, which was mandated by the ballot measure, held its third meeting on Wednesday—two months after the group established tracking and reporting criteria for police activity related to psilocybin post-decriminalization.

Now, thanks to Denver voters’ decision last May, the city is home to the nation’s first government psychedelics decriminalization body, but it is not likely to be the last.

Campaign To Decriminalize Psychedelics In DC Cleared For Signature Gathering

Photo courtesy of Wikimedia/Mushroom Observer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Politics

Pennsylvania Senators Will Consider DUI Protections For Medical Marijuana Patients At Hearing

Published

on

A Pennsylvania Senate committee is set to take up a bill next week that would protect medical marijuana patients from being prosecuted under the state’s “zero tolerance” DUI laws.

The legislation, sponsored by Sen. Camera Bartolotta (R), would amend state statute to require proof of active impairment before a registered patient can be prosecuted for driving under the influence. The current lack of specific protections for the state’s roughly 368,000 patients puts them in legal jeopardy when on the road, supporters say.

Members of the Senate Transportation Committee will explore the issue at a hearing on Tuesday.

Bartolotta first introduced an earlier version of the bill in June 2020. She said at the time that the state needs to “ensure that the legal use of this medicine does not give rise to a criminal conviction.”

Months after the standalone reform legislation was introduced, the Pennsylvania House approved a separate amendment that would enact the policy change.

Pennsylvania legalized medical marijuana in 2016, with the first dispensaries in the state opening in 2018. But the state’s zero-tolerance DUI law still doesn’t reflect those changes. Because it criminalizes the presence of any THC or its metabolites in a driver’s blood—which can be detected for weeks after a person’s last use—the law puts virtually all medical marijuana patients at risk, even if it’s been days since their last use and they show no signs of impairment.

Bartolotta’s bill would require officers to prove a registered patient was actually impaired on the road.


Marijuana Moment is already tracking more than 1,200 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

“Unimpaired patients currently face the risk of being arrested, prosecuted and convicted for using medicinal marijuana that has no bearing on their ability to drive a vehicle,” the senator wrote in a cosponsorship memo late last year. “Given the very serious consequences of a DUI conviction, my legislation will provide critical protections for medicinal cannabis patients by ensuring responsible use of their legal medicine does not give rise to a criminal conviction.”

Several legal cannabis states have enacted per se THC limits in blood, similar to blood alcohol requirements. However, evidence isn’t clear on the relationship between THC concentrations in blood and impairment.

A study published in 2019, for example, concluded that those who drive at the legal THC limit—which is typically between two to five nanograms of THC per milliliter of blood—were not statistically more likely to be involved in an accident compared to people who haven’t used marijuana.

Separately, the Congressional Research Service in 2019 determined that while “marijuana consumption can affect a person’s response times and motor performance… studies of the impact of marijuana consumption on a driver’s risk of being involved in a crash have produced conflicting results, with some studies finding little or no increased risk of a crash from marijuana usage.”

Outside of this bill, Pennsylvania lawmakers have continued to pursue adult-use legalization in the state. Earlier this year, two legislators circulated a memo to build support for a comprehensive reform bill they plan to introduce, for example.

A bipartisan Senate duo is also in the process of crafting legislation to legalize cannabis across the commonwealth. They announced some details of the proposal earlier this year, but the bill has yet to be formally introduced.

Outside the legislature, Gov. Tom Wolf (D) said earlier this year that marijuana legalization was a priority as he negotiated the annual budget with lawmakers. However, his formal spending request didn’t contain legislative language to actually accomplish the cannabis policy change.

Wolf, who signed a medical cannabis expansion bill in June, has repeatedly called for legalization and pressured the Republican-controlled legislature to pursue the reform since coming out in favor of the policy in 2019. Shortly after he did that, a lawmaker filed a separate bill to legalize marijuana through a state-run model.

Lt. Gov. John Fetterman (D), who is running for U.S. Senate, previously led a listening tour across the state to solicit public input on legalization. He’s credited that effort with helping to move the governor toward embracing comprehensive reform. The lieutenant governor even festooned his Capitol office with marijuana-themed decor in contravention of a state law passed by the GOP-led legislature.

Fetterman has also been actively involved in encouraging the governor to exercise his clemency power for cannabis cases while the legislature moves to advance reform.

In May, Wolf pardoned a doctor who was arrested, prosecuted and jailed for growing marijuana that he used to provide relief for his dying wife. That marks his 96th pardon for people with cannabis convictions through the Expedited Review Program for Non-Violent Marijuana-Related Offenses that’s being run by the Board of Pardons.

Overall, legalization is popular among Pennsylvania voters, with 58 percent of residents saying they favor ending cannabis prohibition in a survey released in April.

Another poll released in May found that a majority of voters in the state also support decriminalizing all currently illicit drugs.

80 Top Law Enforcement Officials, Including A Biden Nominee, Urge SCOTUS To Hear Safe Injection Drug Case

Photo courtesy of Mike Latimer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

80 Top Law Enforcement Officials, Including A Biden Nominee, Urge SCOTUS To Hear Safe Injection Drug Case

Published

on

A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—have filed a brief urging the Supreme Court to take up a case on the legality of establishing a safe injection facility where people can use illicit drugs in a medically supervised environment.

The nonprofit organization Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration, and it filed a petition with the nation’s highest court last month to hear the case. Now the group of law enforcement officials associated with Fair and Just Prosecution are calling on the Supreme Court to act in an amicus brief.

“Amici have an interest in this litigation because overdose prevention sites (OPSs) are among the harm reduction and public health interventions that have proven effective in preventing fatal overdoses and diverting people from unnecessary and counterproductive interactions with the justice system,” they wrote. “Amici, many of whom are currently or were previously responsible for enforcing the nation’s drug laws, also believe that the Controlled Substances Act cannot be construed to prohibit operation of a facility designed to address the most acute aspects of this public health emergency.”

If the court agrees to hear the dispute, advocates will be looking toward the Biden Justice Department and whether it will continue the federal government’s opposition to allowing supervised injection facilities. It would be a precedent-setting case that could steer policy for years to come, meaning Safehouse is taking a significant risk by pursuing the appeal of its loss in a lower court before the majority of conservative justices.

“Failing to address the loss of life resulting from drug overdoses—and criminalizing a community-based public health organization working to save lives—will further erode trust in the justice system,” the new brief states. “If there were ever a time to demonstrate that our government values the dignity of human life, that time is now.”

While President Joe Biden hasn’t weighed in directly on safe consumption sites, there’s been a theme within his administration of embracing the general concept of harm reduction for drugs. The White House Office of National Drug Control Policy (ONDCP), for example, said that “promoting harm-reduction efforts” is a first-year priority. In an overview of its objectives, the office said it intends to expand “access to evidence-based treatment,” enhance “evidence-based harm reduction efforts” and promote “access to recovery support services.”

These goals theoretically align with those of Safehouse, which wants to give people with substance use disorders a facility where medical professionals can intervene in the event of an overdose and provide people with the resources to seek recovery.

Among the signatories on the amicus brief are a former deputy assistant attorney general under Obama, district attorneys of Baltimore, Cook County, Dallas County, Los Angeles County, Manhattan, Philadelphia, San Francisco County and Seattle and the former attorneys general of Ohio, Vermont and Virginia.

But one signatory who especially stands out is Rachael Rollins, the district attorney of Suffolk County, Massachusetts who is Biden’s nominee for U.S. attorney of Massachusetts.

“As an elected prosecutor, I have a responsibility to protect every member of my community, which requires moving away from criminal justice responses to substance use disorder,” Rollins said in a press release. “Instead, we must embrace proven public health strategies as potential solutions. Lives depend on it.”

Philadelphia District Attorney Larry Krasner said the drug war “has taken too many lives already, and criminalization has only exacerbated this devastating toll.” He added: “We need a new way forward that allows communities to address the overdose crisis with harm reduction approaches proven to save lives and improve community safety.”

Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.

Safehouse won a battle in a federal district court in 2019 to proceed with the facilities. But in January, the U.S. Court of Appeals for the Third Circuit overturned the decision, ruling that permitting such facilities would violate a 1980s-era federal statute that bars organizations from running operations “for the purpose of unlawfully… using controlled substances.” That law was passed while Biden served in the Senate and helped push punitive drug policies that have had lasting consequences.

“As current and former criminal justice leaders, amici have seen first-hand how the classic ‘war on drugs’ approach to drug control—with its almost exclusive focus on aggressive criminal law enforcement—has exacerbated the overdose epidemic,” the pro-reform prosecutors and cops wrote in the new brief. “This experience confirms that no jurisdiction can arrest its way out of this public health problem. Fatal overdoses are a symptom of substance use disorder, a medical condition requiring a medical response.”

“Distorting federal drug laws to prohibit an [overdose prevention site] or to prosecute its sponsors would further undermine trust in the justice system and faith in the fair and sensible application of our drug laws. Interpreting federal criminal law to bar empirically validated harm reduction measures would make no one safer; it would only impede cooperation between law enforcement and the communities they serve.”

In its original petition to the Supreme Court in the current safe injection site case, Safehouse argued that the justices should “grant review to determine whether” federal statute really does prohibit “non-commercial, non-profit social service agencies…from establishing an overdose-prevention site that includes medically supervised consumption.”

“This question is a matter of life or death for thousands of Philadelphians and many thousands more throughout the country,” it said. “Tragically, while respondents have been pursuing this declaratory judgment against Safehouse, more than 3,200 people died in Philadelphia of drug overdoses—many of which could have been prevented if medical care had been immediately available through supervised consumption services.”

Safehouse also pointed out that Xavier Bacerra, the Biden administration’s secretary of health and human services, was among eight top state law enforcement officials who filed an earlier amicus brief in support of the organization’s safe injection site plan when he served as California’s attorney general.

The organization put the gravity of the case in no uncertain terms, painting a picture of how its proposed facility can save lives.

“When breathing stops, even a brief delay while waiting for medical help to arrive may result in an otherwise preventable overdose death or irreversible injury,” the petition says. “As a result, every second counts when responding to an opioid overdose; as more time elapses, the greater the risk of serious injury and death. Ensuring proximity to medical care and opioid reversal agents like the drug Naloxone at the time of consumption is therefore a critical component of efforts to prevent fatal opioid overdose.”

“Intervention by this Court is warranted to make clear that the federal law does not criminalize this essential public health and medical intervention designed to save lives from preventable overdose death,” it continues.

Safehouse argued that the appeals court’s interpretation of the law “eviscerates the intended boundaries of the statute and would criminalize the operation of legitimate businesses, charities, families, and good Samaritans that serve and reside with those suffering from addiction.”

If the Supreme Court were to take up the case and rule in favor of Safehouse, it could embolden advocates and lawmakers across the country to pursue the harm reduction policy.

The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.

Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.

A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.

At the same time that Safehouse is turning to the Supreme Court, it also announced recently that it will be returning the the federal district court that gave it an initial 2019 victory in support of establishing a safe injection facility before it was overturned in the appeals court.

The organization is making the unique argument that the federal government’s decision to block it from providing the service violates religious freedom by subjecting participants “to criminal penalties for exercising their sincerely held religious beliefs that they have an obligation to do everything possible to preserve life and to provide shelter and care to the vulnerable, including those suffering from addiction.”

In 2018, a congressional subcommittee approved legislation to specifically prohibit Washington D.C. from using local tax dollars to help open safe consumption facilities. But that provision was not enacted and has not been reintroduced since.

A 2020 study found that people “who reported using supervised injection facilities on an at least weekly basis had a reduced risk of dying compared to those who reported less than weekly or no use of this health service.”

Read the amicus brief from the prosecutors on the Safehouse safe injection site case below: 

Safehouse Amicus Sept 2021 by Marijuana Moment

Former GOP Congressman Who Actually Supported Marijuana Reform Enters The Cannabis Industry

Photo courtesy of Jernej Furman.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Former GOP Congressman Who Actually Supported Marijuana Reform Enters The Cannabis Industry

Published

on

Lately it’s come to seem as if most of the former politicians who’ve entered the marijuana industry were unhelpful or downright hostile to legalization when they were in office. But on Friday, a cannabis company announced an addition to its board who disrupts that narrative: a former Republican congressman who has a consistent legislative record of cosponsoring and voting for marijuana reform measures.

The multi-state cannabis businesses Red White & Bloom Brands Inc. (RWB) is bringing on former Rep. Ryan Costello (R-PA) to help it navigate the complicated regulatory space, drawing on his experience in Congress as the company works to expand.

Costello certainly isn’t the only Republican lawmaker who’s made the transition from Capitol Hill to the cannabis market. But he is a rare example of a politician who actually embraced enacting marijuana policy changes while he was in power before standing to profit from the industry. The congressman cosponsored a variety of bills—including ones to shield states that legalize cannabis from federal interference—and supported several reform amendments.

“I’m looking forward to utilizing my 15+ years of service in government, the legal profession, and my familiarity with cannabis policy to be a strategic resource for RWB as it positions itself as a true market leading house of brands in the permitted U.S. marketplace,” Costello said in a press release.

This breaks with a trend that has increasingly frustrated advocates, where it seems the people most inclined to benefit from legalization are those who stood in the way in Congress. The best-known example of that is former GOP House Speaker John Boehner (R-OH), who’s faced criticism from activists over his anti-legalization record while in office before joining the board of marijuana company Acreage Holdings.

While Costello left Congress in 2019 prior to the historic House vote on a standalone bill to federally deschedule cannabis, there are plenty of examples of him supporting more modest reform proposals during his congressional tenure.

He was a cosponsor of legislation to protect state marijuana markets from federal intervention, promote cannabis research, support military veterans’ access to medical marijuana, protect banks that service state-legal cannabis businesses and legalize industrial hemp.

The congressman also voted in favor of floor amendments to shield all state marijuana programs from Justice Department intervention, allow Department of Veterans Affairs doctors to recommend medical cannabis and end hemp prohibition.

In that respect, he was a rare GOP lawmaker. While the issue is increasingly bipartisan among the public, that hasn’t been reflected in Congress. And now Costello is in a position to leverage his legislative experience to advance a marijuana business’s interests.

It’s an exception to the trend.

For example, Tom Price, the former U.S. Department of Health and Human Services (HHS) head under President Donald Trump, is serving as a member of the board of directors for a medical marijuana business in Georgia after he refused to take action to reclassify cannabis under federal law when he had the power to do so. Price consistently voted against marijuana reform measures while serving in Congress.

Former Rep. Steve Buyer (R-IN), who also has a long track record of opposing marijuana legalization efforts, joined a Canadian cannabis company’s board in 2019.

Earlier this month, a New York-based lobbying firm that’s headed by a former Republican U.S. senator announced that it is launching a practice focused on serving cannabis businesses. That former senator, Alfonse D’Amato, racked up a record of supporting the war on drugs while in office.

There is at least one other former GOP congressman who entered the cannabis space with a legislative record supporting marijuana reform. Former Rep. Dana Rohrabacher (R-CA), who championed cannabis reform while in Congress, became an advisory board member for a marijuana company after being voted out of office in 2018.

Separately, President Joe Biden’s pick to head up federal drug policy worked for a major marijuana business last year, according to his financial disclosure reports.

California Activists Cleared To Collect Signatures For Psilocybin Legalization Ballot Initiative

Photo courtesy of WeedPornDaily.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment